About Our Company
AdjuTec Pharma AS is a Norwegian pharmaceutical start-up company that was founded in 2019 based on research in antibiotic products at the University of Oslo (UoO), Norway.
The company management includes five people that together with world-class advisors and a competent board has the required in-house expertise to progress our R&D, business development and fund-raising activities.
AdjuTec's majority owner is the founder Professor Pål Rongved at UoO, and together with competent investors the company is well positioned to take our pipeline products to the market.
The company management includes five people that together with world-class advisors and a competent board has the required in-house expertise to progress our R&D, business development and fund-raising activities.
AdjuTec's majority owner is the founder Professor Pål Rongved at UoO, and together with competent investors the company is well positioned to take our pipeline products to the market.
The company vision is to provide novel antibiotic resistance breakers to meet the imminent threat to modern medicine of antimicrobial resistance (AMR).
AdjuTec's core technology is synthesis of β-lactamase inhibitors (BLIs) that inactivates bacteria resistance enzymes. By taking down bacteria defense we are able to preserve susceptibility of broad-spectrum antibiotics.
Supported by private funding and public grants AdjuTec has completed preclinical development of its lead product APC148 to prepare the application for a First-In-Man study.
AdjuTec's core technology is synthesis of β-lactamase inhibitors (BLIs) that inactivates bacteria resistance enzymes. By taking down bacteria defense we are able to preserve susceptibility of broad-spectrum antibiotics.
Supported by private funding and public grants AdjuTec has completed preclinical development of its lead product APC148 to prepare the application for a First-In-Man study.